Skip to content
Vesalius Therapeutics

A radical new approach to common disease drug development


Now is the time

At Vesalius, we believe it’s time to take a fresh approach to treating the diseases that drive 90 percent of human illness. Our goal is to fundamentally reconceptualize the way we view, diagnose, and treat common diseases.

Progress in treating some of society’s most devastating diseases has not advanced as quickly as it could because our industry has not been defining the problem correctly.

Many of the common diseases we aim to treat – such as heart failure, high blood pressure, type II diabetes, Alzheimer’s disease, NASH, and obesity - have a single diagnosis. However, we now understand that these diseases are not monolithic. They are a constellation of multiple genetically and biologically distinct diseases that affect patients differently.


A new lens on common diseases


Our ContinuumDiscovery platform begins and ends with patients. It discerns previously unrecognized clinical patterns in groups of patients, links these patterns to the combined effects of multiple genes comprising gene circuits, and identifies circuit dependencies that are novel and optimal drug targets to reverse the disease in these patient groups. Our platform utilizes proprietary patient-derived, cell-based experimental models to screen and characterize drug candidates to restore these circuits to healthy functioning.


Our approach combines the power of data science with proprietary technological innovations in artificial intelligence and machine learning, human genetics and genomics, and proprietary human-based experimental models into a uniquely potent discovery engine.

Our Team

At Vesalius Therapeutics, we believe that extraordinary approaches are needed to realize our extraordinary potential. We challenge assumptions and don’t accept the status quo. We are fearless, focused, agile, data-driven and persistent. We are team-focused and continuously learn from each other and our data to make ourselves and our company better.

Our Leadership

Christopher P. Austin, MD
Christopher P. Austin, MD
Ben Munoz, PhD
Ben Munoz, PhD
SVP, Head of Drug Discovery

Board of Directors

Doug Cole, MD
Doug Cole, MD

Managing Partner, Flagship Pioneering
Founder Vesalius

Christopher P. Austin, MD
Christopher P. Austin, MD

Scientific Advisory Board

  • Lee Rubin

    Professor of Stem Cell and Regenerative Biology, Harvard University, and Co-Director, Neuroscience Program, Harvard Stem Cell Institute

  • Paola Arlotta

    Chair, Department of Stem Cell & Regenerative Biology, Harvard University

  • Percy Carter

    Chief Scientific Officer, Blueprint Medicines

  • John A. Todd

    Director, Wellcome Centre for Human Genetics, University of Oxford

  • Wendy Chung

    Chief of Pediatrics, Boston Children's Hospital

  • Tanya Fischer

    Chief Development Officer and Head of Translational Medicine, Biohaven

  • Justin Ichida

    Associate Professor of Stem Cell Biology and Regenerative Medicine, University of Southern California


Join our team

Founded by Flagship Pioneering, Vesalius is taking a new approach to tackling common illnesses. We are patient-focused at our core. We challenge assumptions and don’t accept the status quo.

While we’re pragmatic in our approach and rigorous in our science, we’re still thinking big. Our goal is both ambitious and straight forward: to advance treatments that address some of the most significant challenges in medicine. We believe we’re well on our way.

We’re assembling a world-class team of company builders, innovators, technologists, scientists, and clinicians.


  • 08/01/2022

    Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs

    Biotech investors look at hundreds of startups each year, trying to find the best new companies. Here are the privately held, venture-backed businesses they think will take off.

    Read More
  • 03/01/2022

    Flagship Pioneering Unveils Vesalius Therapeutics to Revolutionize the Treatment of the Diseases that Drive Ninety Percent of Human Illness

    Flagship Pioneering today unveiled Vesalius Therapeutics, a company focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness. Flagship initially committed $75 million to support the development of Vesalius’ platform and initial pipeline of new medicines.

    Read More